| All |
133 (37%) |
284 (32%) |
550 (30%) |
−2% |
139 (39%) |
375 (42%) |
791 (43%) |
1% |
| Acute Myeloid Leukaemia |
X |
11 (48%) |
8 (16%) |
−32% |
X |
10 (44%) |
17 (33%) |
−11% |
| Follicular Lymphoma |
X |
10 (42%) |
8 (32%) |
−10% |
X |
4 (17%) |
4 (16%) |
−1% |
| Hodgkin Lymphoma |
X |
5 (23%) |
8 (25%) |
2% |
X |
11 (50%) |
14 (44%) |
−6% |
| Chronic Lymphocytic Leukaemia |
X |
8 (21%) |
8 (33%) |
12% |
X |
9 (24%) |
17 (71%) |
47% |
| Mantle Cell Lymphoma |
X |
11 (41%) |
12 (40%) |
−1% |
X |
7 (26%) |
8 (27%) |
1% |
| Multiple Myeloma |
2 (33%) |
6 (21%) |
17 (53%) |
32% |
2 (33%) |
15 (54%) |
18 (56%) |
2% |
| Myelodysplastic Syndromes |
X |
7 (29%) |
11 (55%) |
26% |
X |
6 (25%) |
11 (55%) |
30% |
| Waldenstrom Macroglobulinaemia |
X |
1 (13%) |
0 |
−13% |
X |
0 |
3 (38%) |
38% |
| Bone Sarcomas |
4 (14%) |
3 (12%) |
3 (6%) |
−6% |
6 (21%) |
6 (24%) |
8 (17%) |
−7% |
| Early Breast Cancer |
39 (47%) |
32 (43%) |
75 (54%) |
11% |
42 (51%) |
45 (60%) |
100 (73%) |
13% |
| Metastatic Breast Cancer |
3 (60%) |
4 (31%) |
29 (42%) |
11% |
3 (60%) |
7 (54%) |
31 (45%) |
−9% |
| Gastrointestinal Stromal Tumor |
4 (23%) |
6 (29%) |
8 (26%) |
−3% |
8 (47%) |
11 (52%) |
16 (52%) |
0 |
| Hepatocellular Carcinoma |
X |
4 (14%) |
17 (32%) |
18% |
X |
17 (61%) |
29 (55%) |
−6% |
| Localised Colon Cancer |
X |
4 (15%) |
12 (32%) |
17% |
X |
3 (11%) |
16 (42%) |
31% |
| Metastatic Colorectal Cancer |
X |
21 (67%) |
30 (40%) |
−27% |
X |
5 (16%) |
31 (41%) |
25% |
| Melanoma |
X |
0 |
8 (31%) |
31% |
X |
2 (20%) |
9 (35%) |
15% |
| Metastatic Non-Small Cell Lung Cancer |
27 (49%) |
34 (45%) |
71 (42%) |
−3% |
24 (44%) |
34 (45%) |
79 (46%) |
1% |
| Non-Small Cell Lung Cancer |
X |
20 (43%) |
36 (32%) |
−11% |
X |
34 (72%) |
64 (57%) |
−15% |
| Small-Cell Lung Cancer |
X |
6 (30%) |
11 (18%) |
−12% |
X |
3 (15%) |
25 (42%) |
27% |
| Nasopharyngeal Carcinoma |
X |
3 (21%) |
5 (15%) |
−6% |
X |
7 (50%) |
12 (35%) |
−15% |
| Oesophageal Cancer |
8 (38%) |
8 (24%) |
15 (43%) |
19% |
4 (19%) |
14 (41%) |
25 (71%) |
30% |
| Soft Tissue and Visceral Sarcomas |
7 (18%) |
7 (27%) |
8 (26%) |
−1% |
12 (32%) |
6 (23%) |
18 (58%) |
35% |
| Rectal Cancer |
X |
11 (26%) |
9 (47%) |
21% |
X |
28 (65%) |
13 (68%) |
3% |
| Gastric Cancer |
17 (45%) |
18 (39%) |
22 (45%) |
6% |
12 (32%) |
16 (35%) |
20 (41%) |
6% |
| Renal Cell Carcinoma |
11 (27%) |
11 (19%) |
26 (48%) |
29% |
18 (44%) |
24 (42%) |
26 (48%) |
6% |
| Prostate Cancer |
11 (39%) |
18 (45%) |
27 (53%) |
8% |
8 (29%) |
16 (40%) |
14 (28%) |
−12% |
| Marginal Zone Lymphomas |
X |
0 |
1 (6%) |
6% |
X |
5 (36%) |
5 (31%) |
−5% |
| Hereditary Gastrointestinal Cancer |
X |
X |
0 |
X |
X |
X |
8 (25%) |
X |
| Gestational Trophoblastic Disease |
X |
X |
0 |
X |
X |
X |
17 (94%) |
X |
| Philadelphia Chromosome Negative Chronic MPNs |
X |
X |
11 (27%) |
X |
X |
X |
10 (24%) |
X |
| Peripheral T-cell Lymphomas |
X |
X |
0 |
X |
X |
X |
4 (36%) |
X |
| Hairy Cell Leukaemia |
X |
X |
5 (12%) |
X |
X |
X |
3 (7%) |
X |
| Extranodal Diffuse large B-cell lymphoma (DLBCL) and Primary Mediastinal B-Cell Lymphoma |
X |
X |
2 (5%) |
X |
X |
X |
17 (40%) |
X |
| Acute Lymphoblastic Leukaemia |
X |
X |
7 (33%) |
X |
X |
X |
11 (52%) |
X |
| Thymic Epithelial Tumors |
X |
X |
0 |
X |
X |
X |
31 (36%) |
X |
| Penile Cancer |
X |
X |
0 |
X |
X |
X |
0 |
X |
| Leptomeningeal Metastasis |
X |
X |
0 |
X |
X |
X |
0 |
X |
| Brain Metastasis from Solid Tumours |
X |
X |
6 (15%) |
X |
X |
X |
5 (13%) |
X |
| Bladder Cancer |
X |
9 (41%) |
9 (19%) |
−22% |
X |
11 (50%) |
13 (28%) |
−22% |
| Endometrial Cancer |
X |
5 (50%) |
12 (24%) |
−26% |
X |
5 (50%) |
18 (36%) |
−14% |
| Malignant Pleural Mesothelioma |
X |
1 (4%) |
13 (25%) |
21% |
X |
19 (73%) |
21 (40%) |
−33% |
